Shares of EyePoint Pharmaceuticals (EYPT) have gained 12.5% over the past four weeks to close the last trading session at $11.11, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.56 indicates a potential upside of 175.1%.The average comprises nine short-term price targets ranging from a low of $18 to a high of $68, with a standard deviation of $15.13. While the lowest estimat ...

Revenue Performance - Product sales, net decreased by $0.2 million (19%) to $0.7 million for Q3 2024 compared to Q3 2023, driven by lower YUTIQ® sales to ANI[115] - License and collaboration agreement revenue decreased by $4.6 million (32%) to $9.6 million for Q3 2024 due to lower recognition of deferred revenue from YUTIQ® licensing to ANI[116] - Total revenues decreased by $4.7 million (31%) to $10.5 million for Q3 2024 compared to Q3 2023[114] - Product sales, net decreased by $11.1 million, or 82%, to $2.4 million for the nine months ended September 30, 2024, driven by the agreement granting YUTIQ® license and rights to ANI[124] - License and collaboration agreement revenue increased by $10.1 million, or 57%, to $27.9 million for the nine months ended September 30, 2024, due to higher recognition of deferred revenue[125] Expenses and Costs - Research and development expenses increased by $12.2 million (70%) to $29.5 million for Q3 2024[114] - Research and development expenses increased by $12.2 million, or 70%, to $29.5 million for the three months ended September 30, 2024, driven by higher clinical trial costs and personnel expenses[119] - Research and development expenses increased by $42.8 million, or 92%, to $89.6 million for the nine months ended September 30, 2024, driven by higher clinical trial costs and personnel expenses[128] - Cost of sales decreased by $0.5 million, or 39%, to $0.7 million for the three months ended September 30, 2024, primarily due to lower commercial product sales[118] - Sales and marketing expenses decreased by $0.5 million, or 95%, for the three months ended September 30, 2024, due to discontinued YUTIQ® promotion and exit from the commercial business[120] - General and administrative expenses increased by $2.4 million, or 23%, to $13.0 million for the three months ended September 30, 2024, primarily due to higher stock-based compensation and personnel costs[121] Net Loss and Financial Performance - Net loss increased by $16.7 million (133%) to $29.4 million for Q3 2024 compared to Q3 2023[114] - Net cash used in operating activities for the nine months ended September 30, 2024 totaled $90.4 million, primarily due to a net loss of $89.5 million, reduced by $25.8 million of non-cash expenses[139] - Operating cash inflows for the nine months ended September 30, 2023 totaled $25.0 million, primarily due to a net loss of $56.7 million reduced by $10.5 million of non-cash expenses[140] Royalty and Interest Income - Royalty income increased by $0.05 million (20%) to $0.3 million for Q3 2024, attributed to higher non-cash Alimera royalties payable to SWK Funding LLC[117] - Interest income increased by $1.6 million, or 90%, to $3.4 million for the three months ended September 30, 2024, due to higher cash and marketable securities[122] - Interest income increased by $6.5 million, or 142%, to $11.1 million for the nine months ended September 30, 2024, due to higher cash and marketable securities and interest rates[131] Clinical Trials and Product Development - DURAVYU™ 2.7mg demonstrated a gain of +8.9 letters in BCVA and CST improvement of 68.1 microns in the Phase 2 VERONA trial for DME[110] - The company expects to report full topline results for the Phase 2 VERONA trial of DURAVYU™ for DME in Q1 2025[110] Financing and Capital Activities - The company completed a $161.0 million public offering in October 2024, selling 14,636,363 shares at $11.00 per share[109] - Net cash provided by financing activities for the nine months ended September 30, 2024 totaled $12.3 million, including $11.8 million from the issuance of Common Stock and $5.4 million from the exercise of stock options[142] - Net cash used in financing activities for the nine months ended September 30, 2023 totaled $31.4 million, including $40.5 million used to pay off the SVB loan[142] Manufacturing and Facilities - The company opened a 40,000 square foot cGMP-compliant manufacturing facility in Northbridge, MA in October 2024[109] Cash and Investments - The company had cash, cash equivalents, and investments in marketable securities of $253.8 million as of September 30, 2024, and expects to fund operations into 2027[135] - Net cash used in investing activities for the nine months ended September 30, 2024 totaled $123.4 million, including $119.7 million for the purchase of marketable securities and $3.7 million for property and equipment[141] Working Capital and Non-Cash Expenses - Changes in working capital for the nine months ended September 30, 2024 included $26.7 million, with $22.1 million related to deferred revenue from the YUTIQ product rights license agreement[139] - Changes in working capital for the nine months ended September 30, 2023 included $71.2 million, with $57.4 million related to deferred revenue from the YUTIQ product rights license agreement[140] - Non-cash expenses for the nine months ended September 30, 2024 included $28.8 million of stock-based compensation[139] - Non-cash expenses for the nine months ended September 30, 2023 included $8.5 million of stock-based compensation and $1.3 million of loss on extinguishment of debt[140] Regulatory and Reporting - The company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[143]

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.50%. A quarter ago, it was expected that this drug delivery technology company would post a loss of $0.55 per share when it actually produced a loss of $0.58, delivering a surprise of -5.45%.Over the last four ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 000-51122 26-2774444 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 E ...

WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritten public offering of 14,636,363 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,909,090 shares of common stock, at the publi ...

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 12,727,273 shares of its common stock at a public offering price of $11.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $140.0 million, before deducting under ...

EyePoint Pharmaceuticals (EYPT) shares soared 27.6% in the last trading session to close at $12.12. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 19.1% gain over the past four weeks. Earlier this week, the company announced positive interim 16-week data from the ongoing phase II VERONA study evaluating its lead pipeline candidate, Duravyu, for treating patients with diabetic macular edema. Recently, EyePoint Pharmaceuticals als ...

WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares are being offered by EyePoint. In addition, EyePoint intends to grant the underwriters an option for a period of 30 days to purchase up ...

- DURAVYU 2.7mg demonstrated an early and sustained improvement in BCVA with a gain of +8.9 letters compared to baseline - – DURAVYU 2.7mg demonstrated an early and sustained anatomical improvement mirroring BCVA results with a 68 micron reduction in CST - – Favorable safety profile continues with no DURAVYU-related ocular or systemic SAEs to date – – Full topline data anticipated in Q1 2025 – WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company commit ...

WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Morgan Stanley Annual Global Healthcare Conference Forum: 1x1 Investor Meetings Date: Wednesday, September 4, 2024 Baird Global Healthcare Conference Forum: Fireside Chat Date ...